Business
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
Eight Posters Highlighting Pre-Clinical Programs and Leading Gene Therapy Manufacturing and Administration Capabilities LEXINGTON, Mass. and AMSTERDAM, the
About this update from Uniqure N.v.
[{"type":"text","content":"Eight Posters Highlighting Pre-Clinical Programs and Leading Gene Therapy Manufacturing and Administration Capabilities\nLEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress taking place this week in Edinburgh, UK (October 11-14, 2022). “Our presentations at ESGCT highlight both uniQure’s exciting pipeline of gene therapy candidates and our leading gene therapy manufacturing and administration capabilities,” stated Ricardo Dolmetsch, president of research & development at uniQure. “We look forward to sharing new preclinical data from our temporal lobe epilepsy (TLE), Alzheimer’s and ALS research programs, as well as highlighting advances with our enabling technologies and manufacturing capabilities.” Specific details on uniQure’s poster presentations at ESGCT include: Title: Enhancing efficacy and specificity of rAAV5 via small, intermediate, and large peptide insertionsDate and Time: Wednesday, October 12, 2022, 7:30-9:00 p.m. BSTPoster Number: P053 Title: Overexpressing a protective variant while simultaneously lowering toxic APOE as potential treatment for Alzheimer DiseaseDate and Time: Wednesday, October 12, 2022, 7:30-9:00 p.m. BSTPoster Number: P179 Title: Biodistribution and safety of a novel AAV9 gene therapy for treatment of temporal lobe epilepsy shown in non-human primatesDate and Time: Wednesday, October 12, 2022, 7:30-9:00 p.m. BSTPoster Number: P195 Title: Scale-down of AAV production from commercial scale to a high-throughput mini-bioreactor systemDate and Time: Wednesday, October 12, 2022, 7:30-9:00 p.m. BSTPoster Number: P327 Title: linQURETM platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disordersDate and Time: Thursday, October 13, 2022, 5:30-7:15 p.m. BSTPoster Number: P076 Title: AAV-miQURE®-mediated targeting of hexanucleotide repeat expansion-containing transcripts in ALS C9orf72 mouse modelsDate and Time: Thursday, October 13, 2022, 5:30-7:15 p.m. BSTPoster Number: P178 Title: Development of a novel AAV9 gene therapy for the treatment of ...